Abstract:Precise molecular engineering is the most fundamental and even a great challenging task for the development of small organic fluorophores used as phototheranostic agents in multimodal imaging-guided synergistic therapy. To the best of our knowledge, there have been no previous reports regarding the fine fabrication of molecular structure from a proof-of-concept study, providing a single molecule with all phototheranostic modalities. Herein, an electron donating–accepting (D–A) system is constructed by using triphenylamine derivatives as donors and diverse electron-deficient partners as acceptors, yielding aggregation-induced emission luminogens with tunable emission wavelength (up to 933 nm) and light absorption capability (ε up to 6.9 × 104 M–1 cm–1). Notably, by integrating the spin–orbit coupling-promoted carbonyl group and the strong stretching vibrations of −CN to the D–A systems, a highly performing phototheranostic agent, namely, MeTIC, is constructed. When encapsulating MeTIC into nanovehicles, the obtained MeTIC nanoparticles show excellent performance in multimodality theranostics for cancer treatment. This work is expected to provide an organic phototheranostic agent designing principle for potential clinical trials.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.1c00585?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.1c00585</a>.Synthesis and characterization, NMR spectra, spectral data, electrostatic potential, and routine blood indexes (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.1c00585/suppl_file/nn1c00585_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Tuning the Brightness and Photostability of Organic Dots for Multivalent Targeted Cancer Imaging and Surgery.

Photostable Fluorescent Organic Dots with Aggregation-Induced Emission (aie Dots) for Noninvasive Long-Term Cell Tracing

Biocompatible organic dots with aggregation-induced emission for in vitro and in vivo fluorescence imaging

Polymer Dots with Delayed Fluorescence and Tunable Cellular Uptake for Photodynamic Therapy and Time‐Gated Imaging

Molecularly Precise, Bright, Photostable, and Biocompatible Cyanine Nanodots as Alternatives to Quantum Dots for Biomedical Applications

Molecular Design of Ultrabright Semiconducting Polymer Dots with High NIR‐II Fluorescence for 3D Tumor Mapping

Organic Dots with Aggregation-Induced Emission (AIE Dots) Characteristics for Dual-Color Cell Tracing

Donor-Acceptor-Type Conjugated Polymer-Based Multicolored Drug Carriers with Tunable Aggregation-Induced Emission Behavior for Self-Illuminating Cancer Therapy.

Multiple-Armed Tetrahedral DNA Nanostructures for Tumor-Targeting, Dual-Modality in Vivo Imaging.

Ultrabright and Multicolorful Fluorescence of Amphiphilic Polyethyleneimine Polymer Dots for Efficiently Combined Imaging and Therapy.

Cell-Derived N/P/S-Codoped Fluorescent Carbon Nanodots with Intrinsic Targeting Ability for Tumor-Specific Phototheranostics

Tumor-Targeted Fluorescence Imaging and Mechanisms of Tumor Cell-Derived Carbon Nanodots

In vivo cancer targeting and imaging with semiconductor quantum dots

Donor-Acceptor-Donor small molecules for fluorescence/photoacoustic imaging and integrated photothermal therapy

Recent Advances of NIR-II Emissive Semiconducting Polymer Dots for In Vivo Tumor Fluorescence Imaging and Theranostics

Au:Cdhgte Quantum Dots for in Vivo Tumor-Targeted Multispectral Fluorescence Imaging

Precise Molecular Engineering of Small Organic Phototheranostic Agents toward Multimodal Imaging-Guided Synergistic Therapy

Preparation and Application of Fluorescence Dendritic Macromolecular Nanoparticles

NIR-Absorbing Water-Soluble Conjugated Polymer Dots for Photoacoustic Imaging-Guided Photothermal/Photodynamic Synergetic Cancer Therapy

Polymethine-Based Semiconducting Polymer Dots with Narrow-Band Emission and Absorption/Emission Maxima at NIR-II for Bioimaging.

Dye-cored polylysine dendrimer as luminescent nanoplatform for imaging-guided anticancer drug delivery